Jurkat-Human TIGIT (Luc)-Reporter Cell

Introduction

The Jurkat-Human TIGIT (Luc)-Reporter Cell is engineered to express the NFAT response element driving luciferase expression systems and the receptor full-length human TIGIT (Gene ID: 201633), which can be used to evaluate the potency of TIGIT blockade. When co-cultured with target cells expressing human CD155, the TIGIT/CD155 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the TIGIT/CD155 interaction by either anti-TIGIT or anti-CD155 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.

Application

Screen for anti-human TIGIT or anti-human CD155 antibody.

Background

TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains) is an inhibitory receptor expressed on T cells and NK cells. It binds to CD155 (PVR) and CD112 (Nectin-2) on tumor cells and APCs, delivering inhibitory signals that suppress cytotoxicity and cytokine production. TIGIT synergizes with PD-1 to promote immune evasion in cancer.

Product Information